Tracey McNamara, DVM, Veterinary Pathologist, Was a Key Figure in Identifying West Nile Virus in the U.S. Gene Logic Inc. (NASDAQ:GLGC) announced today the appointment of two industry professionals with responsibilities for key activities at Gene Logic Laboratories Inc., the company's nonclinical services subsidiary. -- Suzanne Mullins was named vice president, Quality Systems and Regulatory Compliance for Gene Logic Inc. During her 18 year career, Ms. Mullins has held leadership positions in quality systems and regulatory compliance with well-known industry names such as Astra Zeneca LP, Astra Merck Inc., Glaxo Research Institute, and, most recently, Shire Pharmaceuticals Group PLC. In her new position with Gene Logic, Ms. Mullins is responsible for all quality processes, as well as regulatory compliance and interaction with key regulatory bodies such as the U.S. Food and Drug Administration. -- Tracey McNamara, DVM, DACVP, has joined Gene Logic Laboratories, the nonclinical services division of Gene Logic, as a veterinary pathologist. Dr. McNamara, previously the head of the department of pathology at the Bronx Zoo, achieved renown for her work in the identification of the West Nile Virus outbreak in 1999. Her expertise in comparative pathology and zoonotic diseases--diseases that are communicable from animals to humans--will provide valuable capabilities for vaccine and toxicology studies the Company conducts for pharmaceutical and biopharmaceutical clients. "Recruiting Ms. Mullins and Dr. McNamara is a real achievement for the Company," said V.W. Brinkerhoff III, senior vice president and general manager, Gene Logic Laboratories. "Ms. Mullins' expertise in quality systems and her long experience in regulatory compliance are valuable skills our clients will appreciate. We are committed to quality and continuous improvement; she has much to offer in building on the systems we have in place, to the benefit of our clients and our operations. Dr. McNamara is well-known as a veterinary pathologist for a reason: she is an outstanding scientist. I'm certain she will add immeasurably to the studies we conduct for our pharmaceutical and biotechnology clients. Her work on a West Nile Virus vaccine has given her an excellent background in vaccine development--an area of considerable importance to our clients." Gene Logic Overview Gene Logic is leading the transformation of pharmaceutical research and development with its extensive gene expression databases, pioneering efforts in toxicogenomics, sophisticated bioinformatics expertise, specialty nonclinical services testing capabilities and cutting edge technology program for drug repositioning. Gene Logic technologies and services are used by many of the world's top pharmaceutical and biotechnology companies. Over 150 organizations and government agencies have benefited from Gene Logic's diverse portfolio of drug development services, enabling them to make more informed, more reliable and more predictive decisions at each point in the highly complex and costly drug development process. Founded in 1994, Gene Logic is headquartered in Gaithersburg, Md., with additional research and development facilities in Cambridge, Mass. and Berkeley, Calif. The Company maintains customer support operations in Europe and Asia and currently has about 450 employees worldwide. For more information, visit www.genelogic.com or call toll-free - 1/800/GENELOGIC.
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Gene Logic Inc.  (MM) Charts.
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Gene Logic Inc.  (MM) Charts.